Overview

Study of Oral Atogepant Tablets When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Status:
Not yet recruiting
Trial end date:
2023-10-17
Target enrollment:
Participant gender:
Summary
Migraine is characterized by attacks of throbbing, moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. Adverse events and change in disease activity will be monitored. Atogepant is an investigational drug being developed to prevent chronic migraine. All participants will receive the same treatment. Approximately 125 adult participants will be enrolled at approximately 25 sites in the United States. All participants will receive atogepant oral tablet once daily during the 24-week treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan